In a small trial across ten U.S. research sites, a novel HIV vaccine candidate has shown a result that has eluded scientists ...

A potential breakthrough in the ongoing AIDS crisis could be deprioritized due to the decisions of noted vaccine skeptic Robert F. Kennedy, Jr. In his capacity as the Secretary of Health and Human ...

The government has canceled nearly $500 million in research grants into the revolutionary technology, which experts believe ...

Results from early-stage trial show that 80% of participants who received one of two HIV vaccine candidates produced antibodies against viral proteins.

HIV vaccine efforts have been slowed by the difficulty of getting neutralizing antibodies to target the correct locations of ...

Scientists used a mRNA-based vaccine to reliably trigger antibodies that block HIV infection in people and monkeys ...

Several vaccines for HIV have been tested in animal studies and an early safety trial in people, showing promising results in ...

Many people infected with HIV don’t develop those antibody levels, much less people exposed to the various attempted vaccines throughout the decades. But the hope is that an mRNA vaccine could ...

HIV vaccines have been in development for decades, but a long-lasting one has yet to be successful. The mRNA technology offers new opportunities because mRNA produces a more potent antibody response.

A multiclade env–gag VLP mRNA vaccine elicits tier-2 HIV-1-neutralizing antibodies and reduces the risk of heterologous SHIV infection in macaques. Nature Medicine, 2021; DOI: 10.1038/s41591-021 ...

Moderna's mRNA tech could change the game in the decades-long effort to develop an HIV vaccine. The company said it expects to begin two vaccine trials in humans by the end of 2021.

An experimental HIV vaccine that uses the same mRNA platform technology as the Pfizer and Moderna COVID-19 vaccines shows promise in animals, a new U.S. government-led study finds.